G
Gregory R. Mundy
Researcher at Vanderbilt University
Publications - 315
Citations - 40725
Gregory R. Mundy is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Bone resorption & Osteoclast. The author has an hindex of 111, co-authored 315 publications receiving 39480 citations. Previous affiliations of Gregory R. Mundy include Osaka University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Metastasis to bone: causes, consequences and therapeutic opportunities
TL;DR: The most common human cancers — lung, breast and prostate — have a great avidity for bone, leading to painful and untreatable consequences.
Journal ArticleDOI
Stimulation of bone formation in vitro and in rodents by statins.
Gregory R. Mundy,R I Garrett,Stephen E. Harris,J. Chan,David J. Chen,G. Rossini,Brendan F. Boyce,Ming Zhao,Gloria Gutierrez +8 more
TL;DR: It is shown that the statins, drugs widely used for lowering serum cholesterol, also enhance new bone formation in vitro and in rodents, and may have therapeutic applications for the treatment of osteoporosis.
Journal ArticleDOI
Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
TL;DR: It is reported that both cytokines at 10−7 to 10−9M caused osteoclastic bone r(c)sorption and inhibited bone collagen synthesis in vitro and suggest that at least part of the bone-resorbing activity present in activated leukocyte culture supernatants may be due to these cytokines.
Journal ArticleDOI
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
David E. Hughes,Kenneth R. Wright,Harry L. Uy,Harry L. Uy,Akira Sasaki,Toshiyuki Yoneda,David G. Roodman,David G. Roodman,Gregory R. Mundy,Brendan F. Boyce +9 more
TL;DR: Osteoclast apoptosis may be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.
Journal ArticleDOI
TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
Juan Juan Yin,Katri Selander,John M. Chirgwin,Mark Dallas,Barry Grubbs,Rotraud Wieser,Joan Massagué,Gregory R. Mundy,Theresa A. Guise +8 more
TL;DR: An important role is demonstrated in the development of breast cancer metastasis to bone, via the TGF-beta receptor-mediated signaling pathway in tumor cells, and it is suggested that the bone destruction is mediated by PTHrP.